-
Dilution (already closed) here created a fantastic buying opportunity for Gamblers . Big Phase 3 data for Endometrial Cancer coming in April this could push the sp significantly higher . AEZS is Trading below so the downside is very limited thats why the stock is very attractive for Gamblers .GL
Market Cap : $46 Million
Cash: ~ $65 Million
Price: $0.51
Maxim Maintains Buy On Aeterna Zentaris Ahead Of Zoptarelin-Dox Data
In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) with a $2.00 price target, which implies an upside of 251% from current levels.
Kolbert said, “Zoptarelin-Dox data (interim analysis) in 1H15 represents a key event for the company. We believe that the incremental improvements to this standard of care agent should make it a low risk, high probability of positive outcome event.”
---------------
Zoptarelin Doxorubicin
–Potentially the first FDA approved medical therapy for treating
recurrent endometrial cancer
Interim results in H1-2015 (~128 events)
Significant Market Opportunity Potential
Estimated Potential Annual Market Value
Medical Therapy Treating Recurrent Endometrial Cancer
North America $300–$400 Million
Europe $150–$250 Million
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
Forum Rules